Klaria Interim Report Q1 2023

Report this content

Summary of the Interim Report

Net sales of 6.5 MSEK (0.0 MSEK)

Other income amounted to 0.1 MSEK (0.1 MSEK)

First quarter of 2023

R&D costs for the period amounted to 8.6 MSEK (17.2 MSEK)

Profit after tax amounted to -5.4 MSEK (-20.3 MSEK)

Earnings per share for the quarter amounted to -0.06 SEK (-0.37 SEK)

Cash flow from operating activities amounted to -9.1 MSEK (-19.8 MSEK)

- Cash and cash equivalents on the balance sheet date amounted to 13.1 MSEK (23.0 MSEK)

Cash and cash equivalents on the balance sheet date amounted to 70.7 MSEK (72.1 MSEK)

Klaria receives payment of 2.6 MSEK from Imbrium Therapeutics within the R&D collaboration for Adrenaline Alginate Film

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

 

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.